Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
1.8(c) 1.84(c) 1.83(c) 1.8(c) 1.81(c) Last
1 393 461 813 904 893 459 566 372 997 710 Volume
-4.76% +2.22% -0.54% -1.64% +0.56% Change
More quotes
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Sector
Pharmaceuticals
Calendar
03/05Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating :
More Ratings
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 8,70 M
EBIT 2014 -53,2 M
Net income 2014 -44,3 M
Debt 2014 -
Yield 2014 -
Sales 2015 18,0 M
EBIT 2015 -42,4 M
Net income 2015 -43,9 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 25,3x
Capi. / Sales 2015 12,2x
Capitalization 220 M
More Financials
Latest news on GALENA BIOPHARMA INC
02/19 Galena Biopharma to Report Fourth Quarter and Year End 2014 Financial Results..
02/09 GALENA BIOPHARMA : Other Events, Financial Statements and Exhibits (form 8-K)
02/09 Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 ..
02/05 Galena Biopharma Announces Orexo's Filing of a Patent Infringement Lawsuit Ag..
02/05 Orexo commences patent infringement litigation against Actavis concerning Abs..
01/28 Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
01/20 GALENA BIOPHARMA : Hires Joseph Lasaga as Vice President, Business Development a..
01/15 Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annua..
More news
Sector news Pharmaceuticals - NEC
06:00a BRISTOL MYERS SQUIBB : Hepatitis C cure rate of 97 per cent announced in study o..
05:50aDJMARKET SNAPSHOT : U.S. Stocks: Futures Retreat After Nasdaq Breaks Above 5,000
05:46a ASTRAZENECA : to collaborate with Cambridge Judge Business School
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF